Pharsight

Winlevi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2024

(4 months from now)

US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2024

(4 months from now)

US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents
Jan, 2025

(10 months from now)

US9486458 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2028

(4 years from now)

US10159682 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Aug, 2028

(4 years from now)

US11207332 SUN PHARM Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Nov, 2028

(4 years from now)

US9433628 SUN PHARM Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Feb, 2029

(4 years from now)

US8785427 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2030

(6 years from now)

Winlevi is owned by Sun Pharm.

Winlevi contains Clascoterone.

Winlevi has a total of 8 drug patents out of which 0 drug patents have expired.

Winlevi was authorised for market use on 26 August, 2020.

Winlevi is available in cream;topical dosage forms.

Winlevi can be used as method of treating acne vulgaris with topically applied cortexolone 17a-propionate, method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate.

Drug patent challenges can be filed against Winlevi from 2024-08-26.

The generics of Winlevi are possible to be released after 25 July, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 2024-08-26

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage

WINLEVI family patents

Family Patents